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Dopaminergic neurons in the substantia nigra pars compacta (SNc) degenerate in Parkinson’s 
disease. These neurons robustly express several nicotinic acetylcholine receptor (nAChR) 
subtypes. Smoking appears to be neuroprotective for Parkinson’s disease but the mechanism is 
unknown. To determine whether chronic nicotine-induced changes in gene expression 
contribute to the neuroprotective effects of smoking, we develop methods to measure the effect 
of prolonged nicotine exposure on the SNc neuronal transcriptome in an unbiased manner.
Twenty neurons were collected using laser-capture microscopy and transcriptional changes 
were assessed using RNA deep sequencing. These results are the first whole-transcriptome 
analyses of chronic nicotinic treatment in SNc neurons. Overall, 129 genes were significantly 
regulated: 67 upregulated, 62 downregulated. Nicotine-induced relief of endoplasmic reticulum 
(ER) stress has been postulated as a potential mechanism for the neuroprotective effects of 
smoking. Chronic nicotine did not significantly affect the expression of ER stress-related genes, 
nor of dopamine-related or nAChR genes, but it did modulate expression of 129 genes that 
could be relevant to the neuroprotective effects of smoking, including genes involved in (1) the 
ubiquitin-proteasome pathway, (2) cell cycle regulation, (3) chromatin modification, and (4) DNA 
binding and RNA regulation. We also report preliminary transcriptome data for single-cell 
dopaminergic and GABAergic neurons isolated from midbrain cultures. These novel techniques
will facilitate advances in understanding the mechanisms taking place at the cellular level and
may have applications elsewhere in the fields of neuroscience and molecular biology. The
results give an emerging picture of the role of nicotine on the SNc and on dopaminergic 
neurons.
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Nicotine is the major addictive compound in tobacco, affecting ~20% of the world’s population 
which in turn results in five million deaths worldwide each year [1]. Inhaled nicotine is efficiently 
delivered to the central nervous system where it affects various molecular and cellular 
processes [2, 3]. In the brain, nicotine selectively interacts with its central targets, the nicotinic 
acetylcholine receptors (nAChRs). The 12 nAChR subunits combine in a variety of 
stoichiometries to form pentameric ligand-gated cation channels. The multiple subtypes of 
nAChRs bind nicotine, but with a range of affinities. Nicotine binds to and activates some 
nAChR subtypes (high-sensitivity nAChRs) more than others nAChRs (low-sensitivity nAChRs), 
and can result in activation, then desensitization, of nAChRs. Another level of complexity of the 
actions of nicotine arises from the widespread and non-uniform distribution of nAChR subtypes 
throughout the brain [2]. Hence, nicotine influences many centrally regulated functions, in 
addition to the reward systems. In addition to the commonly reported changes in nicotinic 
acetylcholine receptors (nAChRs) [4-10], chronic nicotine exposure also leads to transcriptional 
changes throughout the brain [11-15]. Given the complexity of these interactions it is 
unsurprising that much remains to be learned about the effects, transcriptional and otherwise, of 
nicotine on the brain.
The substantia nigra pars compacta (SNc) dopaminergic neurons robustly express several 
nAChR receptor subtypes [16]. Nicotine exposure activ tes SNc nAChRs at the plasma 
membrane, increasing firing frequency and therefore resulting in release of dopamine in the 
dorsal striatum. The best-studied effect of chronic nicotine is the upregulation of the nicotinic 
receptor protein subunits themselves. Furthermore, following nicotine exposure, neuronal 
transcriptomes are altered [11-15]. However, the transcriptome-wide response to nicotine in the 
SNc is not clearly understood. 
Parkinson’s disease (PD) is currently an incurable, age-related neurodegenerative disorder.
Although common, the etiology remains poorly understood [17, 18]. Familial causes of PD only 
account for 10% of PD cases, 90% of cases appear to be sporadic, however genetic 
susceptibility may play a role in sporadic PD. Several genes are associated with familial forms 
of PD and include: Pink1 (Park6), DJ-1 (Park 7), UCHL1 (Park 5; proteasomal protein), SNCA 
(Park 1,4), Park2 (Parkin; a ubiquitin E2 ligase) and LRRK2 [19]. In PD there is widespread 
neuronal loss throughout the brain with pronounced neuronal degeneration of DA neurons of the 
SNc. The death of DA neurons in the SNc contributes to the loss of dopamine in the striatum, a 
brain region involved in the control of movement, leading to diagnostic clinical features of 
bradykinesia, rigidity and tremor. Interestingly, a person’s history of tobacco use is inversely 
correlated with his/her risk of Parkinson’s disease (PD) [20, 21]. The protective effects of 
nicotine may be twofold: (1) nicotine exposure activates SNc nAChRs at the plasma membrane, 
increasing firing frequency and therefore increasing release of dopamine in the dorsal striatum,
and (2) the distinct molecular pathways that are regulated by nicotine may exert neuroprotective 
effects. In addition to nicotine, smoked or smoke-cured tobacco releases numerous other 
components, any of which may play an additive role in protection against nigrostriatal damage
[22]. This apparent neuroprotective effect of smoking has been modeled in animals, and the 
data show a strong protective effect of nicotine itself [23-27]. However, smoked or smoke-cured 










tobacco will never be a medically acceptable therapy. Therefore it is important to understand the 
mechanism of apparent inadvertent neuroprotective and/or therapeutic effects of chronic 
exposure to nicotine. In this study we wanted to develop methods to determine whether chronic 
nicotine-induced changes in gene expression contribute to the neuroprotective effects of 
nicotine. Furthermore, there may be transcriptional modifications due to nicotine exposure in the 
SNc in the healthy brain, and we would like to obtain a clear understanding of this.
Here we investigate the effects of chronic nicotine treatment versus saline treatment on wildtype 
mouse SNc neurons. We collect and pool ~20 SNc neurons using laser-capture microscopy, 
then assess transcriptional modifications by deep sequencing. We give the first whole-
transcriptome analysis of nicotinic treatment on SNc cells. Globally, we find that the expression
levels of a total of 129 genes are significantly modulated, 67 are upregulated, and 62 are 
downregulated, by chronic nicotine exposure in our unbiased study. Given the above described 
role of dopamine and nAChRs in the SNc, and the role of endoplasmic reticulum (ER) stress in 
PD [28-33], we first summarize the effect of nicotine on expression of dopamine-related, 
nicotinic receptor, and ER stress-related genes. We find that, broadly speaking, these classes of 
genes are not significantly altered by chronic nicotine exposure. However, our data reveal that 
nicotine exposure modulates expression of 129 genes that could be relevant to the 
neuroprotective effects of smoking including genes involved in (1) the ubiquitin-proteasome 
pathway, (2) cell cycle regulation, (3) chromatin modification, and (4) DNA binding and RNA 
regulation. We also report the first draft transcriptome of single-cell dopaminergic and 
GABAergic neurons isolated from midbrain cultures. Our results give an emerging picture of the 
role of nicotine on the SNc and on dopaminergic neurons. 
2. Materials and methods
2.1 Mice. 
All experiments were conducted in accordance with the guidelines for care and use of animals 
provided by the National Institutes of Health (NIH), and protocols were approved by the 
Institutional Animal Care and Use Committee at the California Institute of Technology. Mice 
were kept on a standard 12 h light/dark cycle at 22°C and given food and water ad libitum. On 
P21, mice were weaned and housed with same-sex littermates. 
2.2 Chronic nicotine administration. 
Chronic nicotine or saline was administered to C57BL6/DBA mice using mini-osmotic pumps 
(model 2002; Alzet, Cupertino, CA) for 14 days as described previously [5, 34]. On the day of 
pump implantation, saline or (−)-nicotine hydrogen tartrate (Sigma, St. Louis) was prepared 
freshly and loaded into the pump to deliver nicotine at 2 mg/kg/h. This concentration has been 
shown to provide maximal nAChR upregulation and provides a blood concentration of 590 nM, 










which is near the peak concentration in the average smokers’ brain [35, 36]. On completion of 
the 14-day nicotine treatment mice were deeply anesthetized with sodium pentobarbital (100 
mg/kg; i.p.) and sacrificed by decapitation. Mice were 4 months of age at the end of chronic 
nicotine/saline treatment.
2.3 Laser capture microdissection
Our methods pipeline for fabricating cDNA libraries via laser capture microdissection [37-39],
and performing RNA-Seq are outlined in Fig. 1. Whole brains from 4 month old male mice (n=2)
were collected (post-mortem interval of < 5 min), fresh frozen over dry-ice, and stored at -80 °C. 
Midbrain cryostat sections (20 μm) were mounted on UV-treated Zeiss Membrane Slides (1.0 
PEN NF), air dried for 5 minutes, and stained with cresyl violet for 1 minute. The sections were
rinsed, dried and then visualized under brightfield illumination at 400X magnification on a Zeiss 
PALM Laser Capture Micro Dissection microscope. Twenty putative DA+ cell bodies from the 
SNc were dissected using multiple low laser energy pulses (see Fig. 2A), and were catapulted
into Zeiss 200 μL adhesive caps. Cell lysis solution (Illumina, San Diego, CA) containing 3’ 
SMART reverse transcription primers and quantitation controls (“spikes”) were then added into 
the pool of cells prior to freezing. For comparison we also generated RNA-Seq libraries from 
200 pg of untreated mouse whole brain RNA (n=2). 
2.4 RNA-Seq library generation
To fabricate our cDNA libraries we prepared amplified cDNA from RNA, using Clontech's 
SMARTer™ Ultra Low RNA system for Illumina Sequencing (Clontech, Mountain View, CA). We
used Clontech's Advantage 2 PCR system for the efficient and accurate amplification of cDNA 
templates by long-distance PCR. Epicentre's Nextera Tn5-mediated tagmentation technology
(Epicentre, Madison, WI) was used as an in vitro transposition method to simultaneously 
fragment and tag the cDNA libraries with Illumina compatible sequencing primers. After quality 
control measures of yield and fragment length distribution were taken using the Qubit 
fluorometer (Invitrogen, Carlsbad, CA) and the Agilent (Santa Clara, CA) Bioanalyzer, 50 bp or
100 bp sequencing reads were generated on the Illumina HiSeq instrument. Each sequencing 
library generated > 20 million uniquely mapping reads. 
2.5 Computational Analysis
50 bp or 100 bp sequence tags were mapped to the mouse genome using TopHat 1.3.2 [41].
We quantified transcript abundance (FPKM: fragments per kilobase per million mapped reads 
(expression values)) using Cufflinks. We annotated the transcripts with genome annotations 
provided by ENSEMBL. We conducted pairwise comparisons and calculated statistical values  
using Cuffdiff, part of the Cufflinks suite, to identify differentially expressed genes. We assessed 
ontology with DAVID [42, 43]. Cuffdiff data with FPKM > 1, a corrected p value of < 0.05 and a 










fold difference of > 1.5 were given as input to Ingenuity Pathway Analysis (IPA) for pathway 
analysis. Gene expression distribution and scatter plots were generated using the R package 
cummeRbund [41]. 
2.6 Immunohistochemistry
Mice (C57BL6) (n=3) were deeply anesthetized with sodium pentobarbital (100 mg/kg; i.p.) and 
perfused transcardially with 15 ml of ice-cold PBS followed by 25 ml of ice-cold 4% 
paraformaldehyde (PFA) in PBS. Brains were removed and postfixed for 2 h at 4°C with the 
same fixative and cryoprotected in PBS containing 30% sucrose until the brain sank. Coronal 
sections (50 μm) were cut on a microslicer and collected into a 12-well tissue culture plate 
containing PBS. Sections were permeabilized (20 mM HEPES, pH 7.4, 0.5% Triton X-100, 50 
mM NaCl, 3 mM MgCl2, 300 mM sucrose) for 1 h at 4 °C followed by blocking (0.1% Triton X-
100, 5% donkey serum in TBS) for 1 h at RT. Slices were incubated overnight at 4 °C in 
solutions containing primary antibodies (diluted in 0.1% Triton X-100, 5% donkey serum in 
TBS). Primary antibodies and final dilutions were as follows: 1:200 rabbit anti-phospho-eIF2α, 
(9721, Cell Signaling), 1:500 sheep anti-tyrosine hydroxylase (TH; AB1542, Millipore), 1:250 
rabbit anti-XBP1 (sc7160; Santa Cruz), 1:50 rabbit anti-GADD153 (CHOP) (sc575; Santa Cruz 
Biotechnology). Sections were washed thrice for 10 min each in TBST (0.1% Triton X-100 in 
TBS) and incubated for 1 h at RT with secondary antibodies (diluted in 0.1% Triton X-100, 5% 
donkey serum in TBS). Secondary antibodies and final dilutions were as follows: 1:1000 goat 
anti-rabbit Alexa 488 (A11008; Invitrogen), 1:1000 donkey anti-sheep Alexa 555 (A21436; 
Invitrogen), 1:1000 donkey anti-mouse Alexa 555 (A31570; Invitrogen), and 1:1000 goat anti-
guinea pig Alexa 555 (A21435; Invitrogen). Sections were then washed four times in TBST for 
10 min each. All sections were mounted on slides and coverslipped with Vectashield (Vector 
Laboratories), then imaged with a Nikon Instruments C1 or A1 laser-scanning confocal 
microscope system equipped with spectral imaging capabilities and a Prior (Rockland) remote-
focus device. A Nikon Plan Apo 10X or 60X oil immersion objective was used, and pinhole 
diameter was 30 μm. Sections were imaged at 12-bit intensity resolution over 512 X 512 pixels 
at a pixel dwell time of 2– 4 μs. Alexa 488 was excited with an argon laser at 488 nm, and Alexa 
555 was excited with a solid-state laser at 561 nm. Imaging was performed using the Nikon 
DEES grating and spectral detector with 32 parallel photomultiplier tubes. Signals from dyes 
were unmixed from background autofluorescence similar to our previous studies [44-47].
2.7 Cell culture and single-cell harvesting
To culture primary midbrain neurons from mouse embryos, ventral midbrain tissue from 
embryonic day 14 embryos was dissected out using standard procedures. Following digestion
with papain (15 min at 37 °C), cells were separated by DNAse treatment and trituration, and
plated at a density of 100,000 cells per dish in poly-L-ornithine and laminin coated imaging 
dishes containing Neurobasal medium supplemented with B27, Glutamax, 1% Hyclone equine 
serum and 100 µm ascorbate. Either control medium (control) or 200 nM nicotine was added to 










the culture for two weeks from day 7 to day 21. Media were changed every 3 days. Single cells 
were harvested on day 21 following a previously reported protocol [48]. Glass capillary tubing 
(Kimax-51, 1.5-1.8 mm o.d.) was cleaned by sonication in ethanol and then baked overnight at
200C to inactivate RNAase. Large bore, glass micropipettes (10-30 m tip diameter) were 
pulled from the tubing using a Sutter P-50 microelectrode puller. Prior to harvesting, we 
removed the media from the culture dishes, rinsed them with 2 ml of Dulbecco’s PBS, and left 1 
ml of Dulbecco’s PBS remaining in the dish for harvesting. Individual cultured neurons were 
identified using a microscope equipped with a 40X phase objective. The pipette was positioned 
over the cell soma using a motorized micromanipulator (Sutter Instrument Co., USA), the cell 
was aspirated into the glass micropipette using gentle suction. The micropipette containing the 
cell was immediately removed from the bathing solution, placed inside a plastic, RNAase-free 
microcentrifuge tube containing 1.5 l of RNAase-free PBS and 0.5 l of an RNAase inhibitor 
solution, and its tip was broken against the side of the tube near the bottom. We applied 
outward pressure to the broken micropipette using a large gauge syringe needle to expel the 
remaining fluid at the tip of the micropipette into the tube. The tube was then centrifuged briefly 
using a desktop centrifuge and then frozen on dry ice. Typically, 16 cells were harvested per 
dish over a 1 h period at ambient temperature. The resultant mRNAs were reverse transcribed 
and amplified to construct single-neuron high-yield cDNA sequencing libraries.
3. Results
3.1 Generation of RNA-Seq libraries from 30 laser captured midbrain cells 
Genome-wide transcriptomic analyses are routinely used to monitor specific tissue-, disease-, 
and cell-type gene expression [49], but it has been technically challenging to generate 
expression profiles from single cells or from a small number of cells. We first generated RNA-
Seq libraries from 30 laser captured midbrain (SNc and VTA) neurons dissected from untreated 
mouse coronal slices (a representative image for laser capture microdissection is given in (Fig. 
2A). Quality control is shown in Fig. 2B, and representative data are shown in Fig. 2C (Libraries 
1-3). We obtained > 30 million 50 bp reads, and detected > 10,000 genes, per library, with an 
excellent distribution of gene expression from 0 to 5000 FPKM. For comparison, we also 
generated high-quality cDNA libraries from 200 pg of mouse whole brain RNA (n=2); 
representative data are shown in Fig. 2C, Library 4. In addition to sequence-based and 
quantitative analysis, gene ontology bioinformatics tools were used to analyze these data. The 
top three gene ontology categories of the 300 most highly expressed genes in midbrain DA+
neurons were determined using DAVID [42, 43]. The top 3 functional categories of genes are 
respiratory chain, metabolite/energy and mitochondrion. These functional categories comply 
with our expectations for dopaminergic neurons. 










3.2 Enrichment of nicotinic receptor transcripts in SNc neurons compared to whole brain tissue
We next generated high-quality RNA-Seq libraries from 20 laser captured SNc cells. We 
conducted Cufflinks and Cuffdiff analysis [41] to compare transcript levels in SNc neurons 
versus whole brain tissue. Overall 1505 genes had significantly different expression in whole
brain (n=2) versus SNc libraries (n=2); 243 genes had significantly higher expression, and 1262
had significantly lower expression, in SNc neurons as compared to whole brain (with no FPKM 
threshold applied). The data show that Chrna3, Chrna4, Chrna6, Chrna5, Chrnb2, Chrnb3 and 
Lynx1 transcripts are present in the SNc neurons. These nAChR genes encode nAChR α3, α4, 
α6, α5, β2, β3 subunits, respectively, and Lynx1 is a nicotinic receptor modulator. We compared 
basal transcript levels for nicotinic receptor genes from these laser captured SNc neurons to 
basal levels in whole brain tissue. Our data show that several nicotinic eceptor gene 
transcripts, namely Chrna4, Chrna6, and Chrnb3, are significantly enriched in SNc cells 
compared to whole brain tissue (Table 1). Here, Chrna4 and Chrna6 are the most abundantly 
expressed nicotinic receptor transcripts. We note that that Lynx1 is expressed, but not enriched, 
in SNc neurons. Other work shows that approximately 90% of SNc neurons are dopaminergic
[50], and as expected, our data show an enrichment of tyrosine hydroxylase (TH) transcripts in 
the SNc neurons compared to whole brain. Tyrosine hydroxylase is enriched 61 fold (42.4 
FPKM vs 2588 FPKM). We also measured an enrichment of other dopamine-related genes 
including Dopa decarboxylase (Ddc) by 84 fold, Slc6a3 (the dopamine transporter DAT) by 207 
fold, and Drd2 (the dopamine D2 receptor) by 128 fold (Table 1).
3.3 Transcriptome-wide analysis of SNc neurons after 14 days of exposure to nicotine at 2 
mg/kg/h
We assessed gene expression on laser captured SNc neurons from mice treated with either 
nicotine or saline, to determine the details of gene activation caused by nicotine exposure in this 
specific neuronal population. We laser captured 20 SNc neurons after 14 days of exposure to 
nicotine at 2 mg/kg/h (n=2), or saline (control) (n=2). In order to make a conservative analysis, 
we applied two criteria. (a) We analyzed data for genes in which both samples (saline and 
nicotine) show transcripts at a level of > 1 FPKM. (b) We required that Cuffdiff determines a 
corrected p value of < 0.05 for significance between the two samples. With these criteria, which 
eliminate false positives, we find that a total of 129 genes are modulated, 67 genes are 
significantly upregulated, and 62 are significantly downregulated, by chronic nicotine exposure.
3.3.1 nAChR subunits
Our study reports the basal transcript expression levels of nAChR α and β subunits and Lynx1
in SNc cells. We investigated the effects of chronic nicotine administration on SNc mRNA levels 
for nAChR α and β subunits. We detected no significant change in nicotinic receptor transcripts
for Chrna4, Chrna6, Chrna3, Chrna5, Chrnb3 and Chrnb2 in nicotine treated versus untreated 
SNc neurons (Table 2). This result agrees with a previous study [51] suggesting that nicotinic 










receptor transcripts are not modulated by nicotine treatment. We also report that Lynx1 is not 
significantly regulated by chronic nicotine treatment. 
3.3.2 Nicotine does not regulate dopamine-related gene transcript levels in wildtype SNc cells.
Animal studies show that the apparent neuroprotective effect of nicotine is at least partially due 
to nicotine itself [23-27]. We investigated whether chronic nicotine administration could 
modulate mRNA levels for dopamine-related genes in the SNc. We examined mRNA levels for 
TH, Ddc, Slc6a3, and Drd2. We found no significant change in dopamine-related transcript 
levels in nicotine treated versus untreated SNc neurons (Table 2). Hence, nicotine does not 
regulate gene transcription for dopamine-related genes in wildtype SNc cells. 
3.3.3 Nicotine treatment does not modulate the expression of ER stress genes in SNc neurons 
of wildtype unstressed animals
ER stress markers have been found in human PD postmortem SNc tissue [30]; hence we were 
interested to test whether nicotine modulates levels of expression of ER stress-associated 
proteins. We first quantified basal transcript levels for ER stress genes from the laser captured 
SNc neurons. Table 2 presents novel basal ER stress gene transcript levels for genes from 
each of the 3 arms of the unfolded protein response (UPR) pathway, in the saline SNc FPKM 
column. This mRNA result is concordant with our protein study for ER stress genes shown in 
Fig. 3. We detected protein expression for several ER stress proteins in the SNc of wildtype 
mice (control). In Fig. 3, protein expression for p-eIF2α, XBP1 and CHOP, each co-stained with 
TH antibody, are detected in the SNc in wildtype coronal brain sections. Next we examined 
whether chronic nicotine treatment modulates mRNA expression of ER stress gene in wildtype 
unstressed SNc neurons. We show that chronic nicotine treatment does not modulate ER stress 
gene levels in wildtype SNc neurons (Table 2).
3.3.4 SNc neuronal-specific transcript modulations induced by chronic nicotine exposure.
As noted above, we observed 129 SNc neuronal-specific transcript modulations induced by 
chronic nicotine exposure. Changes in transcript levels for transcription factors, enzymes, 
transporters and kinase peptidases and nuclear receptors were detected. We next highlight 
some of these results. Significant changes observed between the control and nicotine treated 
samples had corrected p values that ranged from 0.00 to 0.05, some of which are highlighted 
below.
Ubiquitin-proteasome pathway. Chronic nicotine exposure significantly upregulates the E2 
ubiquitin ligase ubiquitin-conjugating enzyme E2J2 (UBE) by 5.06 fold (corrected p value = 
0.03). This enzyme is located in the membrane of the endoplasmic reticulum. However, chronic 
nicotine exposure also significantly decreases the levels of a proteasome subunit and two de-










ubiquitinating enzymes involved in the ubiquitin-proteasome pathway. For example, chronic 
nicotine significantly decreases the transcript levels of the proteasome (prosome, macropain) 
activator subunit 2 (PSME2) by 23.27 fold (corrected p value = 0.01) and of the ubiquitin specific 
peptidase 16 (USP16) gene by 26.89 fold (corrected p value = 0.026) and the ubiquitinating 
specific peptidase 34 (USP34) gene by 10.89 fold (corrected p value = 0.025). Both latter genes 
encode de-ubiquitinating (DUB) enzymes. 
Cell cycle regulators. Chronic nicotine exposure effects the expression of two cell cycle 
regulators: it significantly upregulates cell division cycle 26 (CDC26) by 9.93 fold (corrected p 
value = 0.03) and significantly downregulates cell division cycle 23 (CDC23) by 26.58 fold
(corrected p value = (0.02). Both CDC proteins have ubiquitin-protein ligase activity.
Chromatin modification. Chronic nicotine exposure significantly upregulates the expression of 
chromodomain helicase DNA binding protein 4 (CHD4) by 24.4 fold (corrected p value = 0.04). 
CHD4 has DNA methylation and transcriptional repression activity.
DNA binding and regulation of transcription: Zinc finger protein 76 (ZNF76/ Zfp523) and zinc 
finger with UFM1-specific peptide domain (Zufsp) are both significantly downregulated by 
nicotine by 43 fold (corrected p value = 0.04) and 5.49 fold (corrected p value = 0.04) and play a 
role in DNA binding and regulation of transcription.
RNA processing. Chronic nicotine exposure significantly upregulates the expression of 
polynucleoide adenyltransferase, poly(A) polymerase alpha (PAPOLA) by 13.1 fold (corrected p
value = 0.04). It is involved in the processing of RNA and plays a role in cleavage and 
polyadenylation of pre-mRNA. 
3.4 Novel Single-cell DA and GABAergic transcriptomics 
We aspirated a single neuron from primary mouse midbrain cultures into a glass pipette made in 
a patch-clamp pipette puller. The resultant mRNAs were reverse transcribed and amplified to 
generate a single-neuron, high-yield, good-quality cDNA library. We detected ~5000 genes in 
the single cell libraries. In our midbrain cultures it was not possible to distinguish visually among 
GABAergic and dopaminergic neurons. However, the RNA-Seq data show that single-cell 
transcriptomics unambiguously distinguishes GABAergic from dopaminergic neurons. 
Discrimination is accomplished by quantifying the mRNA levels of the DA+ marker gene TH and
the GABAergic marker gene Gad1 in the single-cell libraries. To the best of our knowledge this 
is the first time single cell RNA-Seq libraries have been generated from DA and GABAergic 
neurons. We present RNA-Seq data for the dopamine-related genes TH, DDC and Slc6a3, and 
for the GABAergic marker gene Gad1, in two single DA+ neurons (n=1 control media, n=1 
nicotine-treated) (Table 3) and in six GABAergic neurons (n=4 control media, n=2 nicotine-
treated) (Table 4). We also report the transcript levels of Chrna6 and Chrnb3 and ER stress 
genes involved in each of the three arms of the UPR in the two single DA+ neurons and in the 
six GABAergic neurons. We report Cufflinks FPKM data in Table 3 and Table 4. We observe
variability in transcript levels for our genes of interest. We also ran Cuffdiff analysis on the 










GABAergic (control) libraries and listed each of the 4 (control) libraries as a biological replicate 
versus the two nicotine treated cells. The Cuffdiff analysis indicates that nicotine treatment does 
not regulate ER stress genes. We do not report Cuffdiff analysis on our control versus nicotine-
treated dopaminergic neurons as our dopaminergic cell number is too small and we wish to 
avoid any unwarranted interpretations.   
We employ a scatter plot to assess cell heterogeneity between two (control) non-treated 
GABAergic libraries (Fig. 4A). The GABAergic single cell RNA-Seq data clearly show 
heterogeneity in expression profiles between single cells of the same type (Fig. 4A). A
Pearson’s correlation analysis on two control GABAergic cell transcriptomes gives r=0.61 (not 
shown). We employ distribution plots to compare the expression density/abundance in these 
two GABAergic cells. For both cells, we observe a broad distribution of transc ipt expression
over 6 orders of magnitude (Fig. 4B).
In summary, we have compiled the first draft transcriptome for dopaminergic and GABAergic 
neurons isolated from midbrain cultures and the main genes of interest are summarized in 
Tables 3 and 4. Our future work will further map out single-cell molecular variability (and 
similarity) associated with cell phenotypes and this will also further highlight cellular pathways 
that are modulated by nicotine at the single-cell level.
4. Discussion
4.1 We have developed a method for assessing the effects of chronic nicotine exposure on 
gene expression in SNc neurons. We have successfully combined laser capture microscopy
and single cell transcriptomics. We also present initial data from the method. 
4.4.1 We observed 129 SNc neuronal-specific transcript modulations induced by chronic 
nicotine exposure. We discuss the relevance of these findings below.
4.1.2 Nicotine affects transcript levels of ubiquitin-proteasome genes in SNc cells; relevance to 
Parkinson’s disease?
In all tissues, the majority of intracellular proteins are degraded by the ubiquitin–proteasome 
pathway [52, 53]. The ubiquitin-proteasome pathway contains enzymes (E1, E2 and E3) that 
link ubiquitin chains onto proteins to mark them for degradation by the 26S proteasome [53]. 
Here, we show for the first time that nicotine modulates the transcript levels of ubiquitin 
enzymes and proteasome in SNc neurons. Specifically, we find that an E2 ligase UBE2J2, and 
a proteasome subunit (PSME2), and two de-ubiquitinating enzymes (USP16 and USP34) are 
significantly modulated by nicotine exposure. As mentioned earlier mutations in the proteasomal 
gene UCHL1 (Park 5; proteasomal protein) or in Park2 (Parkin; a ubiquitin E2 ligase) are 
associated with familial forms of PD.  In both sporadic and familial PD, SNc dopaminergic cells 










show proteasome dysfunction [54-60]. However, there is an inverse correlation between PD and 
person’s history of smoking. It is not unreasonable to suggest that the modulation of the 
ubiquitin proteasome pathway may contribute to the putative neuroprotective effects of nicotine 
and may warrant further investigation. 
Previously Kane et al. [61] showed that, after exposure to nicotine for 14 days, ubiquitin 
enzymes, 20S and 19S proteasomal subunits, and chaperonin-containing complex members 
are upregulated in 2 mm tissue punches from the rat prefrontal cortex (PFC) and are 
downregulated in tissue punches taken from the medial basal hypothalamus (MBH).
Interestingly, their study makes it clear that ubiquitin-proteasome pathways in different brain 
regions have different responses to nicotine. However, such regional brain tissue samples are 
extremely heterogeneous containing hundreds, or perhaps thousands, of cells, with different cell 
types represented in varying proportions. This makes it challenging to make cell-type specific 
inferences. We overcame this challenge by conducting RNA-Seq on a small number of cells,
from the SNc, dissected from their in situ environment.  This allows us to infer that ubiquitin-
proteasome transcripts are regulated in dopaminergic neurons of the SNc, a result that may be 
of relevance to the putative neuroprotective effect of nicotine on the SNc.
In addition to the ubiquitin-proteasome pathway chronic nicoti e also significantly modulates 
other genes that could be relevant to the neuroprotective effects of smoking including genes 
involved in cell cycle regulation, chromatin modification, and  DNA binding and RNA regulation.
4.2 The literature contains many discussions on the relative importance of pulsatile (smoked) vs 
continued application of nicotine. Our preliminary data cannot settle this point. However we note 
these arguments for the relevance of continued application: (1) chewed tobacco, which induces 
brain nicotine levels more slowly than smoking, also has an apparent protective effect, (2) 
upregulation, the best-studied cellular effect of chronic nicotine exposure, occurs quite robustly 
with all tested means of nicotine exposure, including smoking, oral administration, and 
minipumps.
4.3 Chronic nicotine exposure does not regulate nAChR or dopamine-related gene mRNA levels
in SNc cells
As discussed earlier, the degeneration of DA neurons in the SNc contributes to the loss of 
dopamine in the striatum, a brain region involved in the control of movement, leading to 
diagnostic clinical features of bradykinesia, rigidity and tremor. One protective effect of nicotine 
may be that nicotine exposure activates SNc nAChRs at the plasma membrane, increasing 
firing frequency and therefore increasing release of dopamine in the dorsal striatum. Here in this 
study, we were interested to know if chronic nicotine exposure induces changes in expression 
levels of nAChR and dopaminergic related genes. Our data show that in SNc cells chronic 
nicotine exposure does not regulate nAChRs mRNA levels or transcript levels of dopamine-










related genes. These results are concordant with Marks et al. [51]. We also report that the 
mRNA expression of Lynx1 is not modulated by chronic nicotine exposure. 
4.4 Basal levels of ER stress gene transcripts in healthy SNc cells 
Nicotine-induced relief of endoplasmic reticulum (ER) stress has been postulated as a potential 
mechanism for the neuroprotective effects of smoking. Our study assesses whether chronic 
nicotine significantly affects the expression of ER stress-related genes. Our study reveals the 
basal level of ER stress gene transcripts in healthy SNc neurons isolated from intact brains. We 
also find that chronic nicotine exposure does not regulate ER stress gene transcript levels in 
healthy SNc neurons. However, it is possible that ER stress levels may increase in the SNc of 
PD brains caused by protein misfolding and high cellular levels of α-synuclein and other PD-
related proteins. Indeed higher levels of ER stress markers are seen in PD post mortem studies 
[30]. The putative neuroprotective effects provided by nicotine may be cumulative over decades 
and contribute to a prevention of ER stress build-up. If this process occurs, it could contribute to
the inverse correlation of PD and a person’s history of smoking. Therefore, investigating ER 
stress gene transcript levels in SNc cells isolated from a PD model that shows dopaminergic 
cellular dysfunction is warranted.
4.5 Single cell transcriptomics
4.5.1 Single cell transcriptome variability 
Recently it has become feasible to measure cell type specific expression [62-64]. Substantial 
differences in gene expression have been shown for individual cells, even when those cells are 
taken from a seemingly homogenous population [65-70]. Here we use single cell RNA-seq to 
investigate the affects of chronic nicotine on GABAergic and dopaminergic neurons isolated 
from midbrain cultures. We also use this newly developed technique to assess the 
heterogeneity in neuronal populations. We employ a scatter plot to assess the global similarity 
and differences between our GABAergic (control) libraries (Fig. 4A). Shalek et al [65] observed 
that correlation analysis of transcript expression levels between two 10,000–cell population 
replicates gave r=0.98 showing low heterogeneity. However, gene expression differences 
between individual cells are averaged out in such bulk preparation comparisons. In contrast a 
comparison of two single immune cells gave r=0.54, showing high heterogeneity [65]. Here we 
observe that Pearson’s correlation analysis of transcript expression levels of two single 
GABAergic cells gave r=0.61. Molecular and physiological diversity of midbrain GABAergic 
neurons has been highlighted by [71]. As discussed in [65], potential influences on single cell 
heterogeneity include the source of the analyzed cells (in vitro versus ex vivo), the biological 
condition of the individual cells, the cellular microenvironment, and of course short bursts of 
RNA transcription. Variance in gene expression measurements is also influenced by the 
technical difficulty of capturing minute quantities of mRNA in single cell samples.










4.5.2 Effects of nicotine on ER stress genes in single GABAergic neurons
We find that chronic nicotine exposure does not regulate ER stress gene transcript levels in 
GABAergic neurons. This result is concordant with our LCM-captured SNc libraries.
4.6 Concluding remarks.
This study highlights the fact that chronic nicotine exposure has a notable effect on the SNc 
transcriptome, modulating 129 genes and affecting the role of central cellular pathways. These 
effects may contribute to the putative neuroprotective role of nicotine and may be relevant to 
PD. More generally, these results reveal the transcriptional effects of nicotine on the brain.
Clinical trials of nicotine patches in early-stage PD have yielded mixed results, and additional 
trials are under way. We wish to point out the major difference between identifying a target—for 
instance, nAChRs—and understanding the mechanism. The mechanism includes the very 
important question of the target’s localization (ER vs plasma membrane; see graphical 
abstract), as the dosing/pharmacokinetic considerations for subcellular action differ greatly from 
those for plasma membrane action. Specifically, nicotine upregulates nAChRs by 
pharmacological chaperoning at much lower concentrations than those appropriate for 
activation. Mechanism also includes the signaling pathways engaged (see graphical abstract); 
such knowledge will be required both to specify additional drugs that might enhance nicotine 
neuroprotection, and to design suitable analogs that might be more protective than nicotine 
itself.  Only by understanding mechanistic points will the community be able to leverage the 
broad hint from nicotine’s apparent neuroprotective action. 
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Figure 1. Methods pipeline, as performed in our experiments. (1) Dissect out mouse brain, 
freeze (PMI < 5 minutes). (2) Cryostat section at 20 μm (image [33]). (3) Mount on PEN slide, 
stain with Cresyl Violet, rinse, (4) Laser capture micro dissection on Zeiss PALM. (5) lyse cells 
with lysis buffer with dT primer at 72° C. (6) SMART cDNA synthesis; 22 cycles amplification. 
(7) transposon-mediated “tagmentation” of cDNA. (8) cDNA quality control check and 
multiplexed sequencing on Illumina HiSeq. (9) Subsequent computational analysis using 
Tophat, Cufflinks and Cuffdiff [34]. 
Figure 2.  A. Representative image of laser captured SNc neurons, and neurons marked for 
capture (from a 20 μm coronal section stained with Cresyl violet, scale bar = 80 μm).  B. Quality 
check of cDNA, bioanalyser electropherogram showing that most of the cDNA has length > 700 
bp.  C. Gene abundance in cDNA libraries from laser-capture microdissection (LCM) of midbrain 
neurons (SNc and VTA) and whole brain tissue. Libraries #1-3 were each generated from 30 
LCM neurons; #4 from whole brain mRNA. These libraries have excellent representation: 
>10,000 genes are detected at >5 fragments per kilobase of transcript per million fragments 
sequenced (FPKM). Abundance for the three LCM libraries compares well with whole brain 
material. 
Figure 3. TH immunostaining and ER stress proteins in SNc neurons. Representative images of 
CHOP, TH, XBP1 and p-eIF2α protein expression in wildtype coronal brain sections are shown. 
The top panel shows CHOP (red), TH (green) and co-stained (merge) protein expression in SNc 
neurons (60X, scale bars, 50 μm). The top rightmost image shows CHOP (red) protein 
expression in the SNc and SNr, (10X, scale bar, 200 μm). The middle horizontal panel shows 
XBP1 (green), TH (red) and merged protein expression in SNc neurons (60X, scale bar, 50 μm). 
The lower panel shows p-eIF2α (green), TH (red) and merged protein expression in SNc 
neurons (60X, scale bars, 50 μm).    
Figure 4. Single-cell RNA-Seq analysis of GABAergic neurons.  A. Correlation of transcript 
expression levels between two single GABAergic cells (cell (v) and cell (vi)) reveals substantial 
transcriptome heterogeneity.  B. Distribution plots of gene expression reveal a broad range of 
expression levels.
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Two proposed mechanisms for nicotine-mediated transcriptional regulation 
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